Re: 'efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis' by Deng et al.

Zeng, Guangting; Liu, Jing; Liu, Shulan

Re: 'efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis' by Deng et al.

Zeng, Guangting; Liu, Jing; Liu, Shulan.

Zeng G; Department of Pharmacy, The First People's Hospital of Chenzhou, Xiangnan University, Chenzhou, People's Republic of China. Electronic address: 1090651185@qq.com.
Liu J; Department of Pharmacy, The First People's Hospital of Chenzhou, Xiangnan University, Chenzhou, People's Republic of China.
Liu S; Department of Pharmacy, The First People's Hospital of Chenzhou, Xiangnan University, Chenzhou, People's Republic of China.

Clin Microbiol Infect ; 29(6): 814, 2023 06.

Article in English | MEDLINE | ID: covidwho-2288401

Subject(s)

COVID-19; Selective Serotonin Reuptake Inhibitors; Humans; Selective Serotonin Reuptake Inhibitors/adverse effects

Keywords

COVID-19; Efficacy; Fluvoxamine; Safety; Selective serotonin reuptake inhibitors

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Selective Serotonin Reuptake Inhibitors / COVID-19 Type of study: Reviews / Systematic review/Meta Analysis Limits: Humans Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2023 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google